Aldeyra Therapeutics (ALDX) Stock: Buy, Sell, or Hold?
ALDX - Aldeyra Therapeutics, Inc.
$1.17
-0.12 (-9.30%)
▼
5d:
-2.9%
30d:
-21.48%
90d:
-48.68%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When ALDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ALDX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ALDX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ALDX is currently trading at $1.17, which is considered oversold relative to its 30-day fair value range of $1.28 to $1.52. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.2) compared to its historical average (12.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ALDX is in a downtrend. The price is currently testing key support at $1.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.3% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.60 (+464.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALDX is in a downtrend. The price is currently testing key support at $1.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.3% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.60 (+464.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.28 -
$1.52
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.3%)
- BULLISH: Trading 464.1% below Wall St target ($6.60)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.28 -
$1.52
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.15
Resistance Level
$1.44
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.25
Wall Street Target
$6.60
(+464.1%)
PE vs Historical
-4.3 vs 12.8
CHEAP
Share & Embed Analysis
Last updated: October 03, 2026 1:10 AM ET
Data refreshes hourly during market hours. Next update: 2:10 AM
Data refreshes hourly during market hours. Next update: 2:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALDX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
